New ACMG Points to Consider document on use of fetal exome sequencing in prenatal care

New ACMG Points to Consider document on use of fetal exome sequencing in prenatal care

A new Points to Consider document from the ACMG aims to assist referring physicians, laboratory geneticists, genetic counselors and other medical professionals in understanding the complexity and implications of exome sequencing (ES) in prenatal care. Published in ACMG's official journal Genetics in Medicine , the document, "The Use of Fetal Exome Sequencing in Prenatal Diagnosis: A Points to Consider Document of the American College of Medical Genetics and Genomics (ACMG)," is also intended to guide clinical laboratories in the development of protocols and policies related to the increasing use of prenatal exome sequencing. ACMG President Anthony R. Gregg, MD, MBA, FACOG, FACMG said, "In May 2012, the ACMG Board approved "Points to Consider in the Clinical Application of Genomic Sequencing" and, at that time, they did not recommend fetal genomic sequencing. New data speaks to ACMG's concerns raised at that time. Among these are turnaround time and guidance on identifying and reporting variants of unknown clinical significance. "The Use of Fetal Exome Sequencing in Prenatal Diagnosis: A Points to Consider Document of the American College of Medical Genetics and Genomics (ACMG)" is the first ACMG document devoted exclusively to fetal genomic sequencing and the first to provide a framework that laboratories and clinicians can share. As new information emerges, ACMG creates new guidance, which translates to improved patient care." Approximately 2-4% of pregnancies are complicated by significant fetal structural anomalies. Given respect for reproductive autonomy, the ACMG document states that "all patients diagnosed with a fetal anomaly should be offered genetic counseling, including review of options for genetic testing." A genetic diagnosis can assist in determining the fetal prognosis and help guide prenatal care, including decisions of reproductive choice, in utero therapy, delivery planning, and neonatal care, and will potentially decrease morbidity and mortality. A prenatal genetic diagnosis may lead to informed genetic counseling for future reproductive options including preimplantation genetic testing, diagnostic prenatal testing or the possible use of donor gametes. Exome sequencing may be considered when a diagnosis cannot be obtained using routine prenatal methods in a fetus with one or more significant structural anomalies. The utilization of exome sequencing is increasing in prenatal care and the new ACMG document provides an in-depth review of its application in the clinical setting for fetuses with sonographic anomalies. As a trained pediatrician and medical geneticist, one of the most common questions I have heard from parents of a newborn with structural anomalies is: 'What does my child have? What does it mean for my baby? And can this happen again?' To questions regarding diagnosis, prognosis, and recurrence, it is of utmost importance to recognize the underlying cause for the combination of findings first. Fetal exome analysis is now available and has been shown to contribute to earlier diagnosis, which in turn can lead to earlier treatment and better counseling for the family." Maximilian Muenke, MD, FACMG, ACMG Chief Executive Officer Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More